Scarica l'app Stockscreener
9.41
13.51%
1.12
Dopo l'orario di chiusura:
9.57
0.16
+1.70%
Jade Biosciences Inc Borsa (JBIO) Ultime notizie
Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14 - marketscreener.com
Guggenheim upgrades Jade Biosciences stock rating to Buy on transformation - Investing.com Canada
JADE-101 ameliorates IgA nephropathy features in preclinical setting - BioWorld MedTech
Jade Biosciences Presents JADE101 Preclinical Data at the - GlobeNewswire
New IgA Nephropathy Drug Shows 750x Better Binding: JADE101 Outperforms Competitors in Key Metrics - Stock Titan
Jade Biosciences Announces Presentation of Preclinical Data on JADE101 at 62nd European Renal Association Congress - Nasdaq
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress - GlobeNewswire
Breakthrough IgA Nephropathy Treatment: Jade Biosciences Reveals New JADE101 Antibody Data at ERA Congress - Stock Titan
Insider Buying: CEO Tom Frohlich Acquires Shares in Jade Bioscie - GuruFocus
JBIOJade Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences, Inc. Completes Reverse Merger, Launches Nasdaq Trading as JBIO, and Secures $300 Million Financing - Nasdaq
Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 - Stock Titan
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target - Investing.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target By Investing.com - Investing.com India
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com
Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating By Investing.com - Investing.com Nigeria
TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating - Investing.com
Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData
JBIO Stock Price and Chart — NASDAQ:JBIO - TradingView
Jade Biosciences Highlights JADE-001 Progress in Presentation - TipRanks
Jade Biosciences closes merger with Aerovate Therapeutics - Business in Vancouver
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate Therapeutics (AVTE) Declares Special Dividend Amid Merg - GuruFocus
Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals - marketscreener.com
Aerovate approves reverse split ahead of Jade merger - Investing.com
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - The Malaysian Reserve
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - PR Newswire
Aerovate Therapeutics Inc. (AVTE) reports earnings - qz.com
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc.AVTE - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, BMTX, PFIE, ALTR on Behalf of Shareholders - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, BLUE on Behalf of Shareholders - The Malaysian Reserve
Jade Biosciences to Participate in TD Cowen’s 45th Annual - GlobeNewswire
Jade Biosciences, Inc. to Present New Preclinical Data on Jade101 At the 62nd European Renal Association Congress - marketscreener.com
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The MergerIPG, VTS, AVTE, MHLD - The Victoria Advocate
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing - Business Wire
Jade Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
How Fairmount’s Paragon incubator steered two more companies to NASDAQ - BioCentury
Paragon spinout Jade casts reverse merger spell with Aerovate - Fierce Biotech
Paragon launches another company in hot PD-1xVEGF space that goes straight to reverse merger - Endpoints News
Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson - Endpoints News
Jade Biosciences Extends Financing; Total To $95M - FinSMEs
RTW backs Jade Biosciences - QuotedData
Jade Biosciences - The Pharma Letter
Biotech Financing Roundup: Jade Bio’s Launch, Brenig’s Debut, Confo’s Cash & More - MedCity News
Chutes & Ladders—Takeda taps internal leader as head of US oncology business - Fierce Biotech
Jade Biosciences Closes $80M Financing - Contract Pharma
Aerovate scraps late-stage study of lung disorder drug - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
JEADV Clinical Practice | Clinical Dermatology and Venereology Journal - Wiley Online Library
2.13%
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):